Literature DB >> 19733140

A projection of benefits due to fecal occult blood test for colorectal cancer.

Dongfeng Wu1, Diane Erwin, Gary L Rosner.   

Abstract

OBJECTIVES: A prospective study to estimate benefits due to fecal occult blood tests for colorectal cancer are carried out for both males and females, under different screening frequencies.
METHODS: We apply the statistical method developed by Wu et al. (2007) [1] using the Minnesota colorectal cancer study group data, to make Bayesian inference for the lead time, the time of diagnosis advanced by screening for both male and female participants in a periodic screening program. The lead time is distributed as a mixture of a point mass at zero and a piecewise continuous distribution. The two parts of the mixture correspond to two aspects of the screening: the probability of no benefit, or the percentage of interval cases; and the probability distribution of the early diagnosis time. We present estimates of these two measures for males and females by simulation studies using the Minnesota study group data. We also provide the mean, mode, variance, and density curve of the program's lead time by gender. This may provide policy makers important information on the effectiveness of the FOBT screening in colorectal cancer early detection.
RESULTS: The mean lead time increases as the screening time interval decreases for both males and females. The standard error of the lead time also increases as the screening time interval decreases for both genders. Females seem get more benefit than males, in that females usually have a longer lead time than males if both take the test at the same time interval and the lead time mode for females is greater than that of males in the same screening time interval.
CONCLUSION: According to the predictive estimation of the lead time distribution, to guarantee a 90% chance of early detection, it seems necessary for the males to take the fecal occult blood test every 9 months, while the females can take it annually.

Entities:  

Mesh:

Year:  2009        PMID: 19733140      PMCID: PMC2763026          DOI: 10.1016/j.canep.2009.08.001

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  13 in total

1.  Alternative definitions of comparable case groups and estimates of lead time and benefit time in randomized cancer screening trials.

Authors:  Karen Kafadar; Philip C Prorok
Journal:  Stat Med       Date:  2003-01-15       Impact factor: 2.373

2.  Colorectal cancer screening for persons at average risk.

Authors:  William F Anderson; Kate Z Guyton; Robert A Hiatt; Sally W Vernon; Bernard Levin; Ernest Hawk
Journal:  J Natl Cancer Inst       Date:  2002-08-07       Impact factor: 13.506

3.  Offering patients colorectal cancer screening.

Authors:  Timothy R Church
Journal:  J Natl Cancer Inst       Date:  2005-03-02       Impact factor: 13.506

4.  MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening.

Authors:  Dongfeng Wu; Gary L Rosner; Lyle Broemeling
Journal:  Biometrics       Date:  2005-12       Impact factor: 2.571

5.  Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches.

Authors:  T C Prevost; G Launoy; S W Duffy; H H Chen
Journal:  Am J Epidemiol       Date:  1998-09-15       Impact factor: 4.897

6.  Estimating lead time and sensitivity in a screening program without estimating the incidence in the screened group.

Authors:  H Straatman; P G Peer; A L Verbeek
Journal:  Biometrics       Date:  1997-03       Impact factor: 2.571

7.  Estimation of the duration of a pre-clinical disease state using screening data.

Authors:  S D Walter; N E Day
Journal:  Am J Epidemiol       Date:  1983-12       Impact factor: 4.897

8.  [Advantage of immunochemical fecal occult blood test in screening for colorectal cancer].

Authors:  Guy Launoy; C Berchi
Journal:  Bull Cancer       Date:  2005-10       Impact factor: 1.276

9.  Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time.

Authors:  G Launoy; T C Smith; S W Duffy; V Bouvier
Journal:  Int J Cancer       Date:  1997-10-09       Impact factor: 7.396

10.  Estimating key parameters in FOBT screening for colorectal cancer.

Authors:  Dongfeng Wu; Diane Erwin; Gary L Rosner
Journal:  Cancer Causes Control       Date:  2008-08-15       Impact factor: 2.506

View more
  3 in total

Review 1.  Australia's national bowel cancer screening program: does it work for indigenous Australians?

Authors:  Aliki Christou; Judith M Katzenellenbogen; Sandra C Thompson
Journal:  BMC Public Health       Date:  2010-06-25       Impact factor: 3.295

2.  Fecal occult blood test and gastrointestinal parasitic infection.

Authors:  Majed H Wakid
Journal:  J Parasitol Res       Date:  2010-07-26

3.  Early detection of Haemonchus contortus infection in sheep using three different faecal occult blood tests.

Authors:  A V Rodríguez; V Goldberg; H Viotti; G Ciappesoni
Journal:  Open Vet J       Date:  2015-07-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.